No abstract

In the version of this article initially published, Table 1 had several errors. In the 'Immortalized cell lines column, the 'Expansion/ Scalability' was listed as 'very high' and should have been 'unlimited'. In the 'Conditional reprogramming' column 'derivation time' was listed as '2-6 months' and should have been 'a few weeks' , Expansion/Scalabilty was listed as 'Unknown' and should have been 'high' , ' Amenability to high throughput' was listed as 'Unknown' and should have been 'moderate' , 'Modeling early stage cancer and premalignancy' was listed as 'Unknown' and should have been 'Yes' , ' Amenability to genetic manipulation' was listed as 'Unknown' and should have been 'possible' , ' Autologous normal controls' was listed as 'Unknown' and should have been 'yes'. In the 'Tumor-derived iPSCs' column, Expansion/Scalability was listed as 'very high' and should have been 'Unlimited' .

BackgroundOesophageal cancer (OC) survival rates have improved since the widespread adoption of neoadjuvant chemoradiation therapy (NACRT) followed by oesophagectomy (trimodality therapy). Unfortunately, the overall prognosis for patients with locally advanced disease remains poor. In this study, we sought to assess the effect of adjuvant chemotherapy (AC) in patients treated with trimodality therapy.MethodsUsing the National Cancer Database we retrospectively identified 6785 patients with locally advanced (cT1b-T4a, N0-N+, M0) OC who were treated with trimodality therapy from 2006 to 2014. Patients were separated based on receipt of AC (n=463), as well as clinical and pathological lymph node involvement. Overall survival (OS) between groups was compared using the Kaplan-Meier method and Cox proportional hazard modelling.ResultsBased on multivariate analysis, AC was associated with a statistically significantly reduced risk of death (HR 0.77, p<0.001). Subgroup analysis revealed that AC was associated with reduced risk of death compared with NACRT alone in the cN+/pN0 (median OS 64 vs 43 months; p=0.019) and the cN+/pN+ (median OS 27 vs 22 months; p=0.010) groups, but not in the cN0/pN0 (median OS 48 vs 49 months; p=0.253) or cN0/pN+ (median OS 31 vs 24 months; p=0.077) groups.ConclusionAC following trimodality therapy may improve survival in patients with locally advanced OC. Patients who undergo lymph node downstaging may be the most likely to benefit from AC. Prospective studies are needed to confirm this finding.